# Virology and Immunology

> **NIH NIH P01** · UNIVERSITY OF LOUISIANA AT LAFAYETTE · 2020 · $514,852

## Abstract

ABSTRACT – CORE B
The major objective for Core B (Virology/Immunology) is to support Projects 1, 2 and 3 as well as Cores C and
D of this HIVRAD Program Project with extensive virology and immunology expertise. Core B will provide
standardized reagents, assays and analyses in order to achieve inter-project data consistency and cross-
reference. Core B will produce, characterize and standardize stocks of recombinant simian-human
immunodeficiency viruses (SHIVs), SHIV-1157ipEL-p and SHIV-1157ipd3N4, for in vitro and in vivo studies of
Projects 1, 2 and 3, and Cores C and D. To allow high-throughput screening, Core B will use infectious
molecular clones (IMCs) containing the Renilla luciferase reporter gene (LucR IMCs) along with env genes
derived from SHIV-1157ipEL and SHIV-1157ipd3N4. Core B contains a subcontract with the Institute for
Research in Biomedicine (IRB), Bellinzona, Switzerland, headed by Dr. Antonio Lanzavecchia; this subcontract
will generate monoclonal antibodies (mAbs) as IgG1, dimeric IgA1 (dIgA1) and dIgA2 versions for Projects 1
and 2 as well as for Cores C and D. Using standardized and uniform assays, Core B will support the Program
Project by measuring humoral and cellular immune responses, including neutralizing antibody (nAb) titers in
plasma and mucosal secretions. Core B will perform neutralization assays, ELISPOT assays for various
cytokines, B-cell ELISPOTs, CFSE-based antigen-specific T-cell proliferation and intracellular cytokine
staining. Core B also will conduct routine monitoring of all the SHIV-challenged animals for plasma viral RNA
and proviral DNA loads and T-cell subsets.
To provide support to all scientific components of the Program Project, Core B's Specific Aims are:
1. To produce and characterize virus stocks for in vitro assays as well as stocks of SHIV-1157ipEL-p (tier 1)
 and SHIV-1157ipd3N4 (tier 2) for challenge studies in rhesus monkeys (RMs).
2. To generate, produce, purify and characterize all mAbs as dIgA1, dIgA2 and IgG1 versions for passive
 immunization and imaging experiments in RMs.
3. To monitor humoral and cellular immune responses of experimental animals.
4. To monitor the infection status of all experimental RMs in Core C.

## Key facts

- **NIH application ID:** 10008961
- **Project number:** 5P01AI048240-16
- **Recipient organization:** UNIVERSITY OF LOUISIANA AT LAFAYETTE
- **Principal Investigator:** Anton M Sholukh
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $514,852
- **Award type:** 5
- **Project period:** 2000-09-30 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10008961

## Citation

> US National Institutes of Health, RePORTER application 10008961, Virology and Immunology (5P01AI048240-16). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10008961. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*